Standout Papers

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia 2015 2026 2018 2022 1.3k
  1. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia (2015)
    Andrew W. Roberts, Matthew S. Davids et al. New England Journal of Medicine
  2. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial (2023)
    Funda Meric‐Bernstam, Vicky Makker et al. Journal of Clinical Oncology

Immediate Impact

9 from Science/Nature 62 standout
Sub-graph 1 of 22

Citing Papers

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2025 Standout
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
2025 Standout
4 intermediate papers

Works of Soham D. Puvvada being referenced

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
2023 Standout
1500TiP A phase Ib/II, multicenter, open-label, dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd; DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03)
2020
and 2 more

Author Peers

Author Last Decade Papers Cites
Soham D. Puvvada 962 955 367 1085 56 2.5k
Antonella Aiello 905 1015 254 725 61 3.0k
C Jacquillat 583 1209 344 1466 55 2.5k
Elena Hartmann 972 1446 257 1105 80 2.6k
Thomas E. Boyd 711 1172 350 1372 56 2.3k
Laurence Elias 799 1228 310 1425 72 3.2k
Valentin Goede 763 1197 438 1340 75 3.1k
Ulrich Jäger 523 1337 230 1417 85 2.4k
Roberto Giardini 1172 1702 454 661 85 3.2k
Catherine Spier 1967 1790 289 658 73 3.6k
Piers Blombery 641 584 169 853 116 2.3k

All Works

Loading papers...

Rankless by CCL
2026